Jarvik Heart 文献库

1. Economic Issues in Heart Failure in the United States.
Economic Issues in Heart Failure in the United States.
作者: P. Heidenreich et al. 年份: 2022 期刊: Journal of Cardiac Failure DOI: 10.1016/j.cardfail.2021.12.017 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
美国心力衰竭的经济问题。分析了心力衰竭治疗的经济负担、社会影响和医疗资源分配，为政策制定和成本控制提供了重要参考。 引用次数: 124…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

The cost of heart failure care is high due to cost of hospitalization and chronic treatments. Heart failure treatments vary in their benefit and cost. The cost-effectiveness of therapies can be determined by comparing the cost of treatment required to obtain a certain benefit, often defined as an increase in one year of life. This review was sponsored by the Heart Failure Society of America and describes the growing economic burden of heart failure for patients and the health care system in the United States. It also provides a summary of the cost-effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure. Many medications that are no longer under patent are inexpensive and highly cost-effective. These include ACE inhibitors, beta-blockers and mineralocorticoid receptor antagonists. In contrast, more recently developed medications and devices, vary in cost effectiveness, and often have high out of pocket expenses for patients.